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Tuberculosis (TB) remains a common infection
and an important cause of death throughout the
world.1 In 1993, the World Health Organization
(WHO) declared TB a global emergency. TB is
the leading cause of death attributable to a single
infectious pathogen. One-third of the world’s pop-
ulations are at risk of developing the disease.2 In
countries confronted with the human immuno-
deficiency virus (HIV) epidemic, the overlap of
these two populations leads to a rapid acceleration
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Background/Purpose: This retrospective study was conducted to evaluate the drug resistance patterns of
Mycobacterium tuberculosis in a medical center in northern Taiwan between 2003 and 2004 in comparison
to those reported in 1990–1992.
Methods: A total of 611 non-duplicate M. tuberculosis isolates from culture-proven tuberculosis (TB) cases
were tested for drug susceptibility against five first-line anti-TB drugs in a clinical mycobacterial laboratory
using the agar proportional method for isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and strep-
tomycin (SM). The Wayne assay, which measures the activity of pyrazinamide (PZA), was used for PZA
susceptibility testing.
Results: Of 611 patients, including 510 males and 101 females, 70.2% of patients were older than 65 years.
A total of 339 isolates (55.5%) were resistant to one or more drugs. Isolates from patients aged < 25 years
showed a significantly higher drug resistance rate (79.2%) compared with other age groups (p = 0.0312).
Single-drug resistance was observed in 97 (15.9%) of all isolates. Monoresistance to PZA (8.0%) was most
frequent, followed by INH (5.1%), RIF (0.5%), EMB (1.6%), and SM (0.7%). Among the polydrug resistant
isolates (PDR-TB), resistance rates were 35.5% for INH and 27.0% for RIF. One hundred and fifty-nine iso-
lates (26.0%) were resistant to both INH and RIF (multidrug-resistant [MDR] TB); 94.6% of RIF-resistant
isolates were also resistant to INH. The overall drug resistance rates and percentages of PDR-TB and MDR-TB
increased over the 12-year study period (p < 0.001). Based on medical records, primary cases were identified
in 486 (84.7%) out of 574 patients, and resistance to any drug was identified in 268 (55.1%) patients, of
which 130 (26.7%) were MDR-TB. Among the 88 with recurrent TB, 54 (61.4%) were resistant to at least
one drug, and MDR-TB was identified in 29 (33.0%) patients. A history of previous anti-TB therapy was 
a significant factor for overall drug resistance, PZA monoresistance, PDR-TB, and MDR-TB (p < 0.001).
Conclusion: The emergence of M. tuberculosis isolates resistant to anti-TB agents in this hospital, and in
particular among young patients, is alarming. Strict measures to control and prevent drug-resistant TB are
urgently needed. [J Formos Med Assoc 2008;107(3):259–264]
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ORIGINAL ARTICLE
of active TB and of the emergence of multidrug-
resistant (MDR) TB.3 In Taiwan, the annual inci-
dence of TB fell from 64.9/100,000 in 1998 to
62.7/100,000 in 2000, but increased to 64.8/
100,000 in 2001.4,5 High drug resistance rates
have been continually reported in Taiwan.6–13
These figures raised concerns that TB remains a
potential public health problem in Taiwan.
An effective national program for the control
of TB relies upon case-finding and treatment to
eliminate sources of infection. Unfortunately, re-
sistance of Mycobacterium tuberculosis has been en-
countered against all anti-TB drugs. The major risk
factors for the emergence of drug resistant TB are
patient noncompliance and inappropriate admin-
istration of drugs by clinicians. Therefore, the pat-
tern of drug resistance in the health institution is
recognized as a good indicator of the efficiency
of the treatment service.
The objectives of the present study were: (1)
to determine the susceptibility of M. tuberculosis
isolates to first-line anti-TB drugs during the period
2003–2004; and (2) to compare the drug suscepti-
bility patterns of isolates with the results of earlier
reports from this institution in 1990–1992.6
Methods
The present analysis is based on the results of sus-
ceptibility testing of M. tuberculosis strains isolated
at Taipei Veterans General Hospital from January
2003 to December 2004. Taipei Veterans General
Hospital is a 2901-bed teaching hospital in north-
ern Taiwan responsible for the diagnosis and treat-
ment of patients with acute and chronic diseases,
including TB.
Sputum samples were cultured on Löwenstein-
Jensen media. Non-tuberculous mycobacteria were
excluded based on results of biochemical tests of
the niacin test and nitrate test, colony morphol-
ogy and pigmentation, and growth rate on solid
media.14 All enrolled cases were of culture-proven
M. tuberculosis disease. Only the initial isolate of
a patient from whom multiple specimens were
received was tested for drug susceptibility by the
conventional proportion method with Middle-
brook 7H11 agar plate media. As the low pH is
inhibitory to the growth of M. tuberculosis, which
may not precisely detect pyrazinamide (PZA) re-
sistant isolates,15 the Wayne assay, which measures
the activity of PZA, was used for PZA susceptibility
testing.16 Susceptibility was tested in vitro for the
following drugs and concentration (µg/mL): isoni-
azid (INH), 0.2, 1.0; ethambutol (EMB), 5.0, 10.0;
rifampicin (RIF), 1.0, 5.0; streptomycin (SM), 2.0,
10.0; PZA, 25, 50; and with appropriate controls.
Organisms were considered resistant to a given
drug if any growth of 1% or more above the drug-
free control was observed in the presence of the
critical concentration and/or higher concentration
of the drug tested. MDR-TB refers to organisms
that are resistant to two or more anti-TB drugs,
including RIF and INH. Polydrug resistant (PDR) TB
refers to the pattern of drug resistance to several
agents except MDR-TB. The species identification
of the isolates was based on standard microbio-
logical tests: colony morphology, acid-fast stain-
ing and biochemical tests. Overall resistance rate
was defined as the prevalence of drug resistance
among all cases of TB, regardless of prior drug treat-
ment. Based on clinical history, resistance among
new cases was defined as primary resistance, while
resistance among previously treated cases was
defined as acquired resistance.
Statistical analysis of categorical variables was
performed by χ2 test or Fisher’s exact test. A p
value of less than 0.05 was considered statisti-
cally significant.
Results
During the 2-year study period, based on one
isolate per patient, M. tuberculosis isolates from
611 patients in Taipei Veterans General Hospital
were available for analysis. Patients included 510
males and 101 females, 429 (70.2%) of whom were
older than 65 years. The proportion of overall
drug resistance was higher in females (63/101,
62.4%) than in males (276/510, 54.1%), although
the difference was not significant.
W.J. Su, et al
260 J Formos Med Assoc | 2008 • Vol 107 • No 3
The overall drug resistant rate was significantly
higher in those aged<25 years (79.2%; p=0.0312)
compared to those aged 25–45 years (61.4%) and
> 65 years (55.2%) (Table 1). Single-drug resis-
tance was present in 97 (15.9%) of all isolates,
with a higher rate for PZA (8.0%), followed by
INH (5.1%). Resistance to RIF, EMB and SM alone
was 0.5%, 1.6% and 0.7%, respectively (Table 2).
Based on the medical records, primary cases
were identified in 486 (84.7%) out of 574 patients,
while those in the years 1990–1992 were 53.9%.
Among the 486 primary cases, resistance to any
drug was identified in 268 (55.1%) patients, in
whom 130 (26.7%) were MDR-TB. Among the
88 with recurrent TB, 54 (61.4%) were resistant
to at least one drug, and MDR-TB was identified
in 29 (33.0%) patients. A history of previous
anti-TB therapy was significantly associated with
overall drug resistance, PZA monoresistance, and
rates for both PDR-TB and MDR-TB (p < 0.001)
(Table 2).
During the 12-year study period, a significant
increase in drug resistance was observed, com-
paring the years 1990–1992 (22.6%) to 2003–
2004 (55.5%) (p < 0.001) (Figure). Resistance to
INH, RIF, EMB, SM and MDR-TB rose from 14.7%
Mycobacterium tuberculosis resistance in Taiwan
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Table 1. Drug resistance rate by age and prior treatment history, 2003–2004
Drug resistance based on treatment history
Age (yr)
Overall resistance (n = 574)
(n = 611)
Primary Acquired
< 25 19/24 (79.2%)* 5/7 (71.4%) 0
25–45 35/57 (61.4%) 26/41 (63.4%) 6/9 (66.7%)
46–65 48/101 (47.5%) 40/88 (45.5%) 8/16 (50%)
≥ 65 237/429 (55.2%) 197/350 (56.3%) 40/63 (63.5%)
Total 339/611 (55.5%) 268/486 (55.1%) 54/88 (61.4%)
*p = 0.0312 (Fisher’s exact test), compared with rates of other age groups.
Table 2. Comparison of drug resistant patterns of Mycobacterium tuberculosis isolates in two time periods
Overall resistance 2003–2004 (n = 574)*
1990–1992 2003–2004 p Primary Acquired
(n = 651) (n = 611) (n = 486) (n = 88)
Single drug resistance
INH 22 (3.4%) 31 (5.1%) 0.134 26 (5.4%) 1 (1.1%)
RIF 8 (1.2%) 3 (0.5%) 0.227† 2 (0.4%) 0
EMB 16 (2.5%) 10 (1.6%) 0.305 2 (0.4%) 0
SM 18 (2.8%) 4 (0.7%) 0.004† 4 (0.8%) 0
PZA – 49 (8.0%) – 39 (8.0%) 10 (11.4%)‡
Polydrug resistance 202 (41.6%) 42 (47.7%)‡
INH at least 74 (11.4%) 217 (35.5%) < 0.001
RIF at least 61 (9.4%) 165 (27.0%) < 0.001
Multidrug resistance
INH-RIF at least 54 (8.3%) 159 (26.0%) < 0.001 130 (26.7%) 29 (33.0%)‡
INH-RIF-EMB-SM at least 24 (3.7%) 112 (18.3%) < 0.001
INH-RIF-EMB-SM-PZA – 30 (4.9%) –
Any drug 147 (22.6%) 339 (55.5%) < 0.001 268 (55.1%) 54 (61.4%)‡
*Patients in whom previous anti-tuberculosis therapy was identified; †Fisher’s exact test; ‡p < 0.001 (Fisher’s exact test), compared
with patients without previous treatment.
to 40.6% (p < 0.001), from 10.6% to 27.5% (p <
0.001), from 10.3% to 31.3% (p < 0.001), from
9.7% to 29.0% (p<0.001) and from 8.3% to 26.0%
(p < 0.001), respectively.
The majority (94.6%) of RIF-resistant isolates
were also resistant to INH, while 64.1% of INH-
resistant isolates were also RIF-resistant. Thirty
isolates (4.9%) were resistant to all five first-line
agents. A comparison of overall drug resistance
rates in different institutes in Taiwan is summa-
rized in Table 3.
Discussion
While the incidence of TB may be declining in
the general community, the bacteriologic confir-
mation of the disease is increasingly important
due to the changing and varied presentation of
the disease and also due to the higher rates of drug
resistance that are currently being detected. The use
of combinations of anti-TB agents has not pre-
vented drug resistance from occurring in Taiwan.17
The increasing prevalence of anti-TB drug resis-
tance is a consequence of the unsatisfactory quality
of case management of TB, including inadequately
administered therapy based on outdated drug-
susceptibility data. Therefore, it is very important
to find out new TB cases as early as possible, treat
them with a proper regimen and prevent dropout
by directly observed therapy, thus preventing the
emergence of MDR-TB. In addition, clinicians must
have current knowledge of the local epidemiology
of TB, and laboratories should maintain up-to-
date drug susceptibility data on the local isolates
of M. tuberculosis.
The incidence of TB in Taiwan has increased
in recent years, and the prevalence of drug resis-
tance in Taiwan parallels the worldwide situation
for tuberculosis.5–8 The WHO’s global surveillance
W.J. Su, et al
262 J Formos Med Assoc | 2008 • Vol 107 • No 3
Table 3. Drug resistance of Mycobacterium tuberculosis in different institutes in Taiwan
Year
Isolates Overall resistance Resistance rate to individual drugs (%)
Reference
tested (n) rate (%) INH RIF EMB SM MDR
1996–1999 453 34.0 13.9 17.4 8.2 13.7 7.5 7
1996–2000 693 52.4 35.9 13.4 15.7 28.6 11.4 10
2001–2002 252 28.6 21.8 12.7 12.7 8.3 12.7 11
1998–2002 1411 30.5 19.0 6.1 15.7 10.0 5.1 12
2001–2002 513 22.4 16.8 4.9 4.1 12.3 3.9 13
2003–2004 611 55.5 40.6 27.5 31.3 29.0 26.0 This study
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Figure. Drug resistance in isolates of Mycobacterium tuberculosis in two time periods.
for anti-TB drug resistance from 1994 to 1997
had reported high resistance to anti-TB agents in
35 countries,18 and there were repeated reports
in the medical literature of MDR-TB in countries
including Taiwan.19 In recent years, the infrastruc-
tures of TB control in Taiwan were changed to a
centralized, government-budgeted and vertical TB
control system. The clinician has responsibility
for the treatment of TB in general health facilities.
Therefore, routine surveys of drug resistance in
referral hospitals are necessary to provide a guide
to treatment recommendations, and to decrease
the rate of anti-TB drug resistance.
In this study, we reported drug resistance rates
to anti-TB drugs in 2003–2004 compared to those
reported in 1990–1992 at Taipei Veterans General
Hospital using a retrospective hospital-based sur-
veillance. We found a marked increase in drug re-
sistance rates of PDR-TB and MDR-TB in the past
12 years (p < 0.001) (Figure). Single resistance to
specific drugs did not change significantly over
time for all first-line anti-TB agents except the 
decreasing resistance rate to streptomycin, which
may be due to streptomycin being no longer in
use for primary treatment in Taiwan. Many factors
contribute to the emergence of drug-resistant TB
in this hospital, the main one being that this is a
medical center. The increasing rate of primary cases
in 2003–2004 compared to 1990–1992 (84.7%
and 53.9%, respectively) indicated that the worst
cases may be referred to this center, especially pa-
tients who had previously received anti-TB treat-
ment. This suggests the possibility of changes in
referral patterns to this hospital over the period of
study. Secondly, there were 429 (70.2%) patients
older than 65 years, which may result in a higher
resistance rate due to the possibility of reactivation
(Table 1). The overall drug resistance in this study
differs significantly from those of recent reports in
Taiwan (Table 3).7,10–13 However, drug susceptibil-
ity testing has its margins of limitations, varying
from laboratory to laboratory and over time, while
two concentrations are recommended for each an-
tibiotic, so that results obtained by different labo-
ratories or in different years will vary among these
studies. In this study, the lower concentration was
used. If anything, this may have caused a tendency
to overestimate the prevalence of drug resistance
in our study.
As with previous reports, patients younger
than 65 years were found to have a higher rate of
drug resistance.9,12 We also found that the num-
ber of isolates received from patients aged under
25 years was small (n = 24), but the drug resis-
tance rate (79.2%) in this group was significantly
higher than in the other age groups, which were
61.4% in those aged 25–45 years, and 55.2% in
those aged > 65 years (Table 1). Such findings may
suggest that certain groups of people are at a higher
risk of acquiring drug resistance, such as younger
patients. A high index of suspicion and prompt
investigations in young patients may allow for
earlier diagnosis and treatment of TB. More studies
to delineate the effect of age on the presentation
of patients with TB are needed.
MDR-TB is a major public health problem 
because treatment is complicated, cure rates are
well below those for drug-susceptible TB, and pa-
tients may remain infectious for months or years,
despite receiving the best available therapy.18,19
As shown in Table 2, a history of previous anti-TB
therapy was significantly associated with overall
drug resistance, PZA monoresistance, PDR-TB and
MDR-TB. In this study, 94.6% of RIF-resistant iso-
lates were also resistant to INH. Liaw et al also 
reported a MDR-TB rate of 83.7% among RIF-
resistant isolates at a university hospital,12 so RIF
resistance is predictive of MDR-TB. The use of rapid
molecular methods to identify RIF resistance in
cases with risk factors for MDR-TB is likely to
prove highly effective in facilitating early detection
of MDR cases.20 To reduce the problem of resis-
tance for TB, we recommend the use of at least four
drugs (INH, RIF, EMB, PZA) in the first 2 months.
In a recent report from Taiwan, MDR-TB patients
who received ofloxacin were more likely to be
cured, and were less likely to die, fail or relapse.21
However, the role of new fluoroquinolones such
as moxifloxacin in the treatment of MDR-TB needs
to be evaluated.
In conclusion, although the results from this
hospital laboratory are not representative of Taiwan
Mycobacterium tuberculosis resistance in Taiwan
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as a whole, the emergence of drug resistance over
a 12-year period is a challenging issue for future
TB management, and surveys of drug resistance
should be repeated annually at Taipei Veterans
General Hospital. Further studies are needed to
confirm or refute the apparent high levels of re-
sistance among patients with no previous treat-
ment, as reported in the present study. It should
be noted that 4.9% of isolates in this study were
resistant to all five first-line drugs, which highlights
the need for continuous monitoring of drug re-
sistance to anti-TB drugs, and integrating patient
treatment and follow-up with a more accessible
primary health care system such as the Directly
Observed Short Course program to improve poor
compliance, which is an important factor in the
development of drug resistance and treatment
failure.22
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